Lead Sponsor

Bristol-Myers Squibb

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Completion of the protocol-required treatment period in an applicable study of BMS-986165 in moderate-to-severe psoriasis.
•Women must not be pregnant, lactating, or breastfeeding.
•Vaccine Cohort:
•1. Subject must have moderate-to-severe plaque psoriasis, be currently receiving deucravacitinib treatment in the main IM011075 LTE cohort in the United States, Canada, or Poland, and must have completed at least one year of deucravacitinib treatment.

•Any disease or medical condition that the investigator feels that would make the patient unsuitable for this study.
•To be eligible for the study, a participant must not have active signs or symptoms of tuberculosis (TB) as judged by the investigator.
•Vaccine Cohort:
•1. Subject received the Pneumovax 23 vaccine ≤ 5 years before Day 1 or a pneumococcal conjugate vaccine ≤ 1 year before Day 1.
•2. Subject received the Boostrix vaccine (as single or part of a combination vaccine) ≤ 5 years before Day 1.

Related studies

NCT07474792 · Plaque Psoriasis

NCT06857942 · Psoriasis, Overweight or Obesity

NCT06979453 · Plaque Psoriasis

NCT07471048 · Psoriasis

NCT07449234 · Psoriasis

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis